1
|
Braeuninger H, Krueger S, Becher PM, Neumann JT, Bacmeister L, Voss S, Warnke S, Lang V, Zeller T, Laemmle S, El-Armouche A, Kirchhof P, Blankenberg S, Westermann D, Lindner D. Murine matrix metalloproteinase 13 and its human homologue are involved in remodelling processes after myocardial infarction. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): German Centre for Cardiovascular Research (DZHK)
Background
Cardiovascular diseases such as myocardial infarction (MI) are a leading cause of death worldwide. Since matrix metalloproteinases (MMPs) are essential for the cleavage of collagen as well as for the modification of inflammatory proteins and cytokines, they play a substantial role in remodelling processes after MI.
Purpose
Previous results of our group revealed, that Mmp13 expression is upregulated post-MI in mice, while it is downregulated after Ischemia/Reperfusion (I/R), indicating an involvement in remodelling processes. In humans, the functional homologue of Mmp13 is MMP1. Single nucleotide polymorphisms (SNPs) in the promotor of MMP1 can lead to alterations in its gene expression level. We analysed the genotype for 3 MMP1 SNPs in a human cohort containing ~2000 patients who presented to the emergency department with suspected MI to identify their associations with development of MI and outcome after MI.
Methods
The Mmp13 expression in different cardiac cell types was investigated at quiescent stage and under ischaemic conditions, to determine the cellular origin of Mmp13 expression. A MMP13-knockout (KO) mouse model was examined after induction of MI or I/R. Thus, gene expression analysis, histological staining and hemodynamic measurements were conducted to analyse differences between KO and WT as well as between MI and I/R. Out of the human cohort, 2 patient groups (non-MI and MI) were restricted, and Hazard ratios were calculated to evaluate risk for MI and risk for death after MI in dependency of the SNPs.
Results
The Mmp13 expression in macrophages (6.6-fold to control; p=0.0286) and fibroblasts (4.9-fold; p=0.0079) increased significantly after activation with ischaemic secretome of cardiomyocytes, while Mmp13 expression of leucocytes was unaltered. After stimulation with ischaemic secretome of fibroblasts, Mmp13 expression in macrophages (4.3-fold; p=0.0286) and leukocytes (2.3-fold; p=0.0260) was significantly elevated as well. Comparing MI and I/R, the immune cell infiltration revealed significant differences 1-day post-intervention. About 50% of WT mice but only few KO mice died (p=0.0107) after MI due to cardiac rupture. Moreover, KO mice showed an improved cardiac function compared to WT mice after MI. Risk for death was significantly altered between the investigated genotypes in 2 of 3 investigated SNPs in the BACC cohort.
Conclusion
Activated macrophages and leucocytes express high levels of Mmp13 in cell culture experiments. The infiltrating immune cell types are different between MI and I/R, which might lead to differences in Mmp13 expression in these models. MMP13 KO mice are protected from cardiac rupture after MI and unveiled improved cardiac function 28 days post-MI. SNPs of the human homologue of Mmp13 – MMP1 – showed an association of MMP1 with remodelling processes after MI.
Collapse
Affiliation(s)
- H Braeuninger
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - S Krueger
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - PM Becher
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - JT Neumann
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - L Bacmeister
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - S Voss
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - S Warnke
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - V Lang
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - T Zeller
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - S Laemmle
- Dresden University Of Technology, Department of Pharmacology and Toxicology , Dresden , Germany
| | - A El-Armouche
- Dresden University Of Technology, Department of Pharmacology and Toxicology , Dresden , Germany
| | - P Kirchhof
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - S Blankenberg
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - D Westermann
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| | - D Lindner
- University Heart & Vascular Center Hamburg , Hamburg , Germany
| |
Collapse
|
2
|
Künzel S, Newe M, Künzel K, Zimmermann N, El-Armouche A, Günther C. 359 Anti-osteopontin treatment with mesalazine improves fibroblast dysfunction in radiation- induced morphea. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Bornstein SR, Guan K, Brunßen C, Mueller G, Kamvissi-Lorenz V, Lechler R, Trembath R, Mayr M, Poston L, Sancho R, Ahmed S, Alfar E, Aljani B, Alves TC, Amiel S, Andoniadou CL, Bandral M, Belavgeni A, Berger I, Birkenfeld A, Bonifacio E, Chavakis T, Chawla P, Choudhary P, Cujba AM, Delgadillo Silva LF, Demcollari T, Drotar DM, Duin S, El-Agroudy NN, El-Armouche A, Eugster A, Gado M, Gavalas A, Gelinsky M, Guirgus M, Hansen S, Hanton E, Hasse M, Henneicke H, Heller C, Hempel H, Hogstrand C, Hopkins D, Jarc L, Jones PM, Kamel M, Kämmerer S, King AJF, Kurzbach A, Lambert C, Latunde-Dada Y, Lieberam I, Liers J, Li JW, Linkermann A, Locke S, Ludwig B, Manea T, Maremonti F, Marinicova Z, McGowan BM, Mickunas M, Mingrone G, Mohanraj K, Morawietz H, Ninov N, Peakman M, Persaud SJ, Pietzsch J, Cachorro E, Pullen TJ, Pyrina I, Rubino F, Santambrogio A, Schepp F, Schlinkert P, Scriba LD, Siow R, Solimena M, Spagnoli FM, Speier S, Stavridou A, Steenblock C, Strano A, Taylor P, Tiepner A, Tonnus W, Tree T, Watt F, Werdermann M, Wilson M, Yusuf N, Ziegler CG. The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease. Horm Metab Res 2021; 53:204-206. [PMID: 33652492 DOI: 10.1055/a-1377-6583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Currently, we are experiencing a true pandemic of a communicable disease by the virus SARS-CoV-2 holding the whole world firmly in its grasp. Amazingly and unfortunately, this virus uses a metabolic and endocrine pathway via ACE2 to enter our cells causing damage and disease. Our international research training programme funded by the German Research Foundation has a clear mission to train the best students wherever they may come from to learn to tackle the enormous challenges of diabetes and its complications for our society. A modern training programme in diabetes and metabolism does not only involve a thorough understanding of classical physiology, biology and clinical diabetology but has to bring together an interdisciplinary team. With the arrival of the coronavirus pandemic, this prestigious and unique metabolic training programme is facing new challenges but also new opportunities. The consortium of the training programme has recognized early on the need for a guidance and for practical recommendations to cope with the COVID-19 pandemic for the community of patients with metabolic disease, obesity and diabetes. This involves the optimal management from surgical obesity programmes to medications and insulin replacement. We also established a global registry analyzing the dimension and role of metabolic disease including new onset diabetes potentially triggered by the virus. We have involved experts of infectious disease and virology to our faculty with this metabolic training programme to offer the full breadth and scope of expertise needed to meet these scientific challenges. We have all learned that this pandemic does not respect or heed any national borders and that we have to work together as a global community. We believe that this transCampus metabolic training programme provides a prime example how an international team of established experts in the field of metabolism can work together with students from all over the world to address a new pandemic.
Collapse
Affiliation(s)
- S R Bornstein
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- University Hospital Zurich, Department of Endocrinology and Diabetology, Zurich, Switzerland
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - K Guan
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - C Brunßen
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - G Mueller
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - V Kamvissi-Lorenz
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | | | - R Trembath
- Department of Medical & Molecular Genetics, King's College London, London, UK
| | - M Mayr
- School of Cardiovascular Medicine and Science, Faculty of Life Science & Medicine, KCL, London, UK
| | - L Poston
- Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK
| | - R Sancho
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - S Ahmed
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - E Alfar
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - B Aljani
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T C Alves
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - S Amiel
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - C L Andoniadou
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Craniofacial Development and Stem Cell Biology, KCL, London, UK
| | - M Bandral
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - A Belavgeni
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - I Berger
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Birkenfeld
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
| | - E Bonifacio
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - T Chavakis
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - P Chawla
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - P Choudhary
- Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A M Cujba
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - L F Delgadillo Silva
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - T Demcollari
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - D M Drotar
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Duin
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- Centre for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany
| | - N N El-Agroudy
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A El-Armouche
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A Eugster
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - M Gado
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Gavalas
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - M Gelinsky
- Centre for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany
| | - M Guirgus
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Hansen
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - E Hanton
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - M Hasse
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - H Henneicke
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Heller
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - H Hempel
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Hogstrand
- Department of Nutritional Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - D Hopkins
- Department of Diabetic Medicine, King's College Hospital NHS Foundation Trust and KCL, London, UK
| | - L Jarc
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - P M Jones
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - M Kamel
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - S Kämmerer
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A J F King
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Kurzbach
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - C Lambert
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | | | - I Lieberam
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - J Liers
- Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - J W Li
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - A Linkermann
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - S Locke
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - B Ludwig
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
- University Hospital Zurich, Department of Endocrinology and Diabetology, Zurich, Switzerland
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T Manea
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - F Maremonti
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - Z Marinicova
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - B M McGowan
- Department of Diabetes and Endocrinology, London, UK
| | - M Mickunas
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - G Mingrone
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- Università Cattolica del Sacro Cuore, Rome, Italy
| | - K Mohanraj
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - H Morawietz
- Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - N Ninov
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - M Peakman
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - S J Persaud
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - J Pietzsch
- Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - E Cachorro
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - T J Pullen
- School of Life Course Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - I Pyrina
- Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - F Rubino
- Department of Diabetes Research, School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - A Santambrogio
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - F Schepp
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - P Schlinkert
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - L D Scriba
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - R Siow
- Vascular Biology & Inflammation Section, School of Cardiovascular Medicine & Sciences, British Heart Foundation of Research Excellence, King's College London, London, UK
| | - M Solimena
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
- Molecular Diabetology, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - F M Spagnoli
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - S Speier
- Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich at the University Hospital Carl Gustav Carus and Medical Faculty, Dresden, Germany
| | - A Stavridou
- Center for Regenerative Therapies Dresden, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - C Steenblock
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - A Strano
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - P Taylor
- Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK
| | - A Tiepner
- Institute of Pharmacology and Toxicology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - W Tonnus
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - T Tree
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - F Watt
- Centre for Stem Cells and Regenerative Medicine, King's College London, London, UK
| | - M Werdermann
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| | - M Wilson
- School of Life Course Sciences, Faculty of Life Sciences & Medicine, KCL, London, UK
| | - N Yusuf
- Peter Gorer Department of Immunobiology, Guy's Hospital, London, UK
| | - C G Ziegler
- Department of Medicine III, Medical Faculty Carl Gustav Carus, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Germany
| |
Collapse
|
4
|
Klapproth E, Kuenzel S, Guenscht M, Lorenz K, Weber S, Guan K, El-Armouche A. ADAM10 inhibition improves survival and augments cardiac function after myocardial infarction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background and purpose
Following myocardial infarction (MI), adverse fibrotic remodeling with extensive deposition of extracellular matrix (ECM) components has substantial consequences for the contractility of the ventricle finally leading to terminal heart failure (HF). Recently, inhibition of ECM-remodeling enzymes is discussed as potential treatment option for HF, especially following MI. The metalloprotease ADAM10 plays a crucial role in the development of the cardiovascular system and HF patients show elevated serum levels of the ADAM10 substrates CXCL16 and FasL. However, the causal role of ADAM10 in cardiovascular diseases has not been investigated. Here we evaluate the so far unknown role of ADAM10 in heart failure and after MI.
Methods and results
Our study capitalized from human atrial tissue biopsies, a cardiomyocyte-specific ADAM10 knockout (ADAM10 KO) mouse model as well as pharmacological ADAM10 inhibition following MI. ADAM10 expression analysis revealed elevated protein levels in HF patients compared to non-failing hearts. Upon MI, ADAM10 KO and pharmacological ADAM10 inhibition (GI254023X) significantly improved overall survival, significantly enhanced cardiac function (fractional area shortening - FAS, ejection fraction - EF) and significantly reduced infarct sizes. Compared to the high potential angiotensin receptor neprilysin inhibitor (ARNi) LCZ696, ADAM10 inhibition and combined ADAM10i/LCZ696 treatment resulted in preservation of cardiac function that was superior to sole LCZ696 treatment. Mechanistically, this functional improvement was due to reduced shedding of the ADAM10 substrate Notch1, induction of angiogenesis and an ADAM10-dependend inactivation of the NLRP3 inflammasome
Conclusion
Our data suggest that ADAM10 targeting is highly efficient for improving post-infarction cardiac function. Due to its overexpression in heart tissue of HF patients, ADAM10 could be a potential molecular target to improve therapy after MI. In terms of overall survival and pathophysiological remodeling following MI, our data suggest a greater potential of the ADAM10i/LCZ696 combinatorial therapy than sole LCZ696 treatment.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): German Heart Foundation/ German Foundation of Heart Research
Collapse
Affiliation(s)
- E Klapproth
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - S Kuenzel
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - M Guenscht
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - K Lorenz
- University of Wuerzburg, Institute of Pharmacology and Toxicology, Wuerzburg, Germany
| | - S Weber
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - K Guan
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - A El-Armouche
- Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Institute of Pharmacology and Toxicology, Dresden, Germany
| |
Collapse
|
5
|
Kuenzel S, Klapproth E, Kuenzel K, Piorkowski C, Mayr M, Wagner M, Dobrev D, Rausch J, Ravens U, Weber S, El-Armouche A. PLK2 is a novel regulator of osteopontin-driven fibrosis and diastolic dysfunction in permanent atrial fibrillation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3671] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background and aim
Atrial fibrillation (AF) is frequently accompanied by cardiac fibrosis and diastolic heart failure. Due to the heterogeneous nature and complexity of fibrosis, the knowledge of the underlying pathomechanisms is limited. Thus, effective antifibrotic pharmacotherapy is missing. The objective of this study was to decipher the role of polo-like kinase 2 (PLK2) in the pathogenesis of cardiac fibrosis and left ventricular diastolic dysfunction. We put particular emphasis on the identification of profibrotic downstream targets of PLK2, which can serve as therapeutic targets.
Methods and results
This study was based on human atrial tissue biopsies and peripheral blood samples, a PLK2 knockout mouse model, a canine tachy-pacing model and specific pharmacological interventions on cardiac fibroblasts. In human atrial AF tissue samples, PLK2 was 50% downregulated by hypoxia-induced promoter methylation compared to sinus rhythm (SR) control. Confirmatory analysis of a canine tachy-pacing model showed PLK2 downregulation exclusively in the atria but not in the ventricles. Specific pharmacological inhibition as well as genetic deletion of PLK2 led to a striking myofibroblast phenotype. Discovery proteomics revealed that the global knockout of PLK2 resulted in de novo secretion of the inflammatory cytokine osteopontin (OPN) in cardiac fibroblasts and concomitant ventricular fibrosis in the PLK2 knockout mouse model. An ELISA analysis of peripheral blood samples of AF patients with electrophysiologically proven fibrosis, confirmed significantly increased OPN plasma concentrations compared to SR and non-fibrosis AF controls. Consequently, echocardiography on PLK2 KO mice revealed left ventricular diastolic dysfunction, tachycardia and fibrosis-typical surface ECG anomalies (PQ and QRS prolongation). Mechanistically, we identified the ERK1/2 signaling pathway as the molecular link between reduced expression of PLK2 and elevated osteopontin transcription. In a reverse translational attempt, we successfully tested the capability of 5-amino-salicylic acid (5-ASA) to inhibit osteopontin transcription and to reverse a TGF-β-induced myofibroblast phenotype in vitro. Currently the long-term administration of 5-ASA is tested in PLK2 knockout mice to evaluate the therapeutic potential to prevent cardiac fibrosis and diastolic heart failure development.
Conclusion and clinical impact
We identified PLK2 as an epigenetically regulated kinase involved in the pathophysiology of fibrosis in AF. PLK2 knockout mice can serve as a model of diastolic heart failure wherein OPN is a promising therapeutic target. Our results strengthen the current hypothesis that atrial fibrillation is not only an ion channel disease but a complex systemic disorder. Restoration of physiological PLK2 expression and blockade of osteopontin release with 5-ASA may constitute valuable new drug targets for the prevention and treatment of fibrosis and diastolic heart failure in AF.
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Faculty of Medicine, Carl Gustav Carus, Dresden, “MeDDrive Start” Grant
Collapse
Affiliation(s)
- S Kuenzel
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| | - E Klapproth
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| | - K Kuenzel
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| | - C Piorkowski
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - M Mayr
- King's College London, The James Black Centre, London, United Kingdom
| | - M Wagner
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - D Dobrev
- Institute of Pharmacology, Essen, Germany
| | - J.S.E Rausch
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| | - U Ravens
- University Heart Center Freiburg, Institut für Experimentelle Kardiovaskuläre Medizin, Freiburg, Germany
| | - S Weber
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| | - A El-Armouche
- Dresden University of Technology, Insitute of Pharmacology and Toxicology, Dresden, Germany
| |
Collapse
|
6
|
Kirstein B, Neudeck S, Kronborg MB, El-Armouche A, Gaspar T, Piorkowski J, Wechselberger S, Zedda A, Tomala J, Mayer J, Wagner M, Ulbrich S, Richter U, Huo Y, Piorkowski C. P457Incidence of LA fibrosis and substrate-based AF ablation success rates in HF patients. Europace 2020. [DOI: 10.1093/europace/euaa162.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
The author(s) received no specific funding for this work.
Background
In heart failure (HF) patients, sinus rhythm maintenance after catheter ablation for atrial fibrillation (AF) is mandatory to achieve better long-term outcome. Presence of left atrial (LA) fibrosis significantly attenuates ablation success rates. Incidence of LA fibrosis and the effect of an individualized substrate-based ablation concept on rhythm outcome in HF patients with AF is unclear.
Methods
This study investigated 103 patients (64 years, 69% men) with persistent AF (79%) and left ventricular (LV) dysfunction (EF 33% IQR [25; 38]) undergoing first time AF ablation. Identification of LA fibrosis and selection of ablation strategy were based on sinus rhythm voltage mapping. All patients received pulmonary vein isolation (PVI). LA fibrosis ablation was individualized by (i) homogenization of small areas, (ii) linear lesions connecting fibrosis and anatomical obstacles and (iii) linear lesions isolating large fibrotic areas. Rhythm outcome was measured by continuous device monitoring (AF detection ≥ 6 min) or Holter-ECG. A total post-procedural AF burden < 0.1% was defined as successful rhythm control.
Results
LA fibrosis in the overall cohort, in paroxysmal and persistent AF patients was detected in 39/103 (38%), 6/22 (27%) and 33/81 (41%), respectively. After 11 ± 5 months and 1.2 procedures/patient, freedom from AF recurrence was similar between patients with and without LA fibrosis (33/39 (84%) vs. 54/64 (84%); p = 0.485). With continuous monitoring, 73/87 (84%) patients recorded a total AF burden < 0.1%. There was no significant difference in AF burden outcome between patients with and without LA fibrosis (3.1% SD ±17.4 vs. 2.2% SD ±8.1; p = 0.4). No correlation between presence or extent of LA fibrosis and AF burden was found; p = 0.299.
Conclusion
A substantial number of HF patients with AF have no evidence of LA fibrosis. Among HF patients with LA fibrosis, individualized substrate-based AF ablation beyond PVI was able to achieve similar ablation success.
Collapse
Affiliation(s)
- B Kirstein
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Neudeck
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - M B Kronborg
- Aarhus University Hospital, Cardiology, Aarhus, Denmark
| | - A El-Armouche
- University Hospital Dresden, Pharmacology, Dresden, Germany
| | - T Gaspar
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Piorkowski
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Wechselberger
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - A Zedda
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Tomala
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Mayer
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - M Wagner
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Ulbrich
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - U Richter
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - Y Huo
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - C Piorkowski
- Heart Center - University Hospital Dresden, Dresden, Germany
| |
Collapse
|
7
|
Droth K, El-Armouche A, Andresen D, Bestehorn KP. 2406Role of implantation access on complication rates in pacemaker implantation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
The implantation access (IA) either via vena cephalica (VC) or vena subclavia (VS) is the usual procedure in pacemaker implantation (PI). Valid data on head-to head comparisons between access via CV and VS regarding serious complications are missing.
Purpose
We analyzed potential associations between the type of implantation access and complication rates in a real world data set with 69.957 cases.
Methods
The 2013 dataset of the German Federal Council, containing information about all 1st pacemaker implantations for Germanywas analyzed. First two cohorts of patients treated via CV or CS access were compared for all relevant variables through descriptive statistics. Secondly all patient-clusters with exactly the same risk-/condition-vector were identified based on the following variables: age, sex, ASA classification (ASA 1–ASA 5), leading symptom, indication for implantation, etiology, ejection fraction (EF), estimated need of stimulation, and all possible 1:1 exact matchings were compared.
Results
Out of the total cohort of 69,957 patients (mean age 76.2 years, 43.3% females, VC access 36%, VS access 64%) 19,643 pairs with identical profile of all factors contained in the database could be identified. These pairs of all 1:1 matchings had following profile: age 77.07 years, ASA 1 to 4 6.3%, 2 45.0%, 46.9%, 4 1.7%, leading symptoms (dizziness 51.9%, singular cardiac syncope 10.3%, recurring syncope 28,7%), pacemaker indication (AV-Block II/III 11.6%/26.3%, sick sinus syndrome 39,8%, bradycardia in atrial fibrillation 20.0%), unknown etiology 90.3%, estimated need of stimulation (permanent (>90%) 20.9%, frequent (5–90%) 70.2%, rare (<5%) 8.9%), EF (≤35%: 0.4%: 35, 50%: 9.1%, >50%: 79.9%, unknown: 10.5%).
Intra- and post-procedural complication [C] rates different between VC and VS are: at least one C: 2.6% (VC), 3.0% (VS) p=0.018; surgical C with need for intervention (haematothorax, pericardial effusion, pouch hematoma): 0.5% (VC), 1.0% (VS) p=0.005; asystole: 0.1% (VC), 0.2% (VS) p=0.047; pneumothorax: 0.1% (VC), 0.7% (VC) p<0.001; dislocated atrial lead: 0.8% (VC), 0.6% (VS) p=0.027. Intra-hospital mortality was 1.0% (VC), 1.1% (VS) p=0.521.
Conclusion
Our analysis of a large-scale database shows that in patients with first pacemaker implantation the overall rate of complications is relatively low. But even after adjustment for available risk factors there are differences between the access routes: whereas VS access route is associated with statistically significant higher risk of overall complications, i.e. surgical complications, asystole, pneumothorax the VC access has a greater risk of dislocated atrial lead. In view of the two times higher rate of implantations via VS (64 vs. 36%) the clinical implications should be considered when choosing the access route and the VC access should be preferred.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- K Droth
- Dresden University of Technology, Institute of Clinical Pharmacology, Dresden, Germany
| | - A El-Armouche
- Dresden University of Technology, Institute of Clinical Pharmacology, Dresden, Germany
| | - D Andresen
- Charite - Campus Mitte (CCM), Cardiology, Berlin, Germany
| | - K P Bestehorn
- Dresden University of Technology, Institute of Clinical Pharmacology, Dresden, Germany
| |
Collapse
|
8
|
Westhofen S, Dreher L, El-Armouche A, Vitzhum H, Reichenspurner H, Ehmke H, Schwoerer P. Altered Electrophysiological Remodeling Induced by Mechanical Unloading in Phospholamban Deficient Mice. Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- S. Westhofen
- Universitäres Herzzentrum Hamburg, Hamburg, Germany
| | - L. Dreher
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | | | - H. Vitzhum
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | | | - H. Ehmke
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - P. Schwoerer
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
9
|
Mollenhauer M, Lange M, Remane L, Friedrichs K, Wagner M, Geisler A, Rudolph TK, Carrier L, El-Armouche A, Klinke A, Baldus S, Rudolph V. P3441Anti-arrhythmic effects of nitrated fatty acids during acute myocardial ischemia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Mollenhauer
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - M Lange
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - L Remane
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - K Friedrichs
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - M Wagner
- Dresden University of Technology, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - A Geisler
- University Medical Center Hamburg Eppendorf, Cardiology, Hamburg, Germany
| | - T K Rudolph
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - L Carrier
- University Medical Center Hamburg Eppendorf, Cardiology, Hamburg, Germany
| | - A El-Armouche
- Dresden University of Technology, Institute of Pharmacology and Toxicology, Dresden, Germany
| | - A Klinke
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - S Baldus
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| | - V Rudolph
- Cologne University Hospital - Heart Center, Cardiology, Cologne, Germany
| |
Collapse
|
10
|
Eiringhaus J, Fischer TH, Dybkova N, Saadatmand A, Pabel S, Weber S, Wang Y, Koehn M, El-Armouche A, Maier LS, Hasenfuss G, Sossalla S. P5703Selective activation of cardiac protein phosphatase 1 is of antiarrhythmic potential in human diseased myocardium. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Eiringhaus
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - T H Fischer
- Hospital Coburg, Dept. of Cardiology, Angiology & Pneumology, Coburg, Germany
| | - N Dybkova
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - A Saadatmand
- University Hospital of Heidelberg, Dept. of Molecular Cardiology & Epigenetics, Heidelberg, Germany
| | - S Pabel
- University Hospital Regensburg, Dept. of Cardiology & Pneumology, Regensburg, Germany
| | - S Weber
- Dresden University of Technology, Dept. of Pharmacology & Toxicology, Dresden, Germany
| | - Y Wang
- European Molecular Biology Laboratory, Cell Biology and Biophysics Unit, Heidelberg, Germany
| | - M Koehn
- University of Freiburg, Centre for Biological Signalling Studies (BIOSS) and Faculty of Biology, Freiburg, Germany
| | - A El-Armouche
- Dresden University of Technology, Dept. of Pharmacology & Toxicology, Dresden, Germany
| | - L S Maier
- University Hospital Regensburg, Dept. of Cardiology & Pneumology, Regensburg, Germany
| | - G Hasenfuss
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - S Sossalla
- University Hospital Regensburg, Dept. of Cardiology & Pneumology, Regensburg, Germany
| |
Collapse
|
11
|
Fahmi M, Richter K, Dybkova N, Vettel C, Dewenter M, Fischmeister R, Piorkowski C, El-Armouche A, Sossalla S, Wagner M. P514Investigating the mechanistic role of PDE2 in cardiac arrhythmia. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Fahmi
- Dresden University of Technology, Integrative Center of Pharmacology and Toxicology, Dresden, Germany
| | - K Richter
- Dresden University of Technology, Integrative Center of Pharmacology and Toxicology, Dresden, Germany
| | - N Dybkova
- University Medical Center Gottingen (UMG), Heart Center Gottingen, Department of Cardiology and Pneumology, Gottingen, Germany
| | - C Vettel
- Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
| | - M Dewenter
- University Hospital of Heidelberg, Molecular Cardiology and Epigenetics, Heidelberg, Germany
| | - R Fischmeister
- University of Paris-Sud 11, INSERM UMR-S 1180, Chatenay-Malabry, France
| | - C Piorkowski
- Heart Center Dresden, Department of Invasive Electrophysiology, Dresden, Germany
| | - A El-Armouche
- Dresden University of Technology, Integrative Center of Pharmacology and Toxicology, Dresden, Germany
| | - S Sossalla
- University Hospital Regensburg, Clinic and Polyclinic for Internal Medicine, Regensburg, Germany
| | - M Wagner
- Heart Center Dresden, Department of Invasive Electrophysiology, Dresden, Germany
| |
Collapse
|
12
|
Schwab DM, Tilemann L, Bauer R, Heckmann M, Jungmann A, Wagner M, Burgis J, Vettel C, Katus HA, El-Armouche A, Müller OJ. AAV-9 mediated phosphatase-1 inhibitor-1 overexpression improves cardiac contractility in unchallenged mice but is deleterious in pressure-overload. Gene Ther 2018; 25:13-19. [DOI: 10.1038/gt.2017.97] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 10/16/2017] [Accepted: 11/20/2017] [Indexed: 11/09/2022]
|
13
|
Rathjens F, Renger A, Dewenter M, Toischer K, El-Armouche A, Zimmermann W, Zelarayan L, Zafiriou M. 1982Molecular mechanisms of arrhythmia upon TBX5 loss. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Wagner M, Weber S, El-Armouche A. Linking superinhibitory PLN mutations to CaMKII activation: a new arrhythmogenic mechanism in genetic DCM? Cardiovasc Res 2015; 107:5-6. [DOI: 10.1093/cvr/cvv163] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Döker S, Dewenter M, El-Armouche A. Tofacitinib. AKTUEL RHEUMATOL 2014. [DOI: 10.1055/s-0034-1395610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- S. Döker
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| | - M. Dewenter
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| | - A. El-Armouche
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| |
Collapse
|
16
|
Neuber C, Uebeler J, Schulze T, Sotoud H, El-Armouche A, Eschenhagen T. P368Guanabenz interferes with ER stress and exerts protective effects in cardiac myocytes. Cardiovasc Res 2014. [DOI: 10.1093/cvr/cvu091.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Affiliation(s)
- S. Döker
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| | - M. Dewenter
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| | - A. El-Armouche
- Institut für Pharmakologie, Universitätsmedizin Göttingen
| |
Collapse
|
18
|
Vettel C, Lämmle S, Ewens S, Cervirgen C, Emons J, Ongherth A, Dewenter M, Lindner D, Westermann D, Nikolaev VO, Lutz S, Zimmermann WH, El-Armouche A. PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways. Am J Physiol Heart Circ Physiol 2014; 306:H1246-52. [PMID: 24531807 DOI: 10.1152/ajpheart.00852.2013] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Recent studies suggest that the signal molecules cAMP and cGMP have antifibrotic effects by negatively regulating pathways associated with fibroblast to myofibroblast (MyoCF) conversion. The phosphodiesterase 2 (PDE2) has the unique property to be stimulated by cGMP, which leads to a remarkable increase in cAMP hydrolysis and thus mediates a negative cross-talk between both pathways. PDE2 has been recently investigated in cardiomyocytes; here we specifically addressed its role in fibroblast conversion and cardiac fibrosis. PDE2 is abundantly expressed in both neonatal rat cardiac fibroblasts (CFs) and cardiomyocytes. The overexpression of PDE2 in CFs strongly reduced basal and isoprenaline-induced cAMP synthesis, and this decrease was sufficient to induce MyoCF conversion even in the absence of exogenous profibrotic stimuli. Functional stress-strain experiments with fibroblast-derived engineered connective tissue (ECT) demonstrated higher stiffness in ECTs overexpressing PDE2. In regard to cGMP, neither basal nor atrial natriuretic peptide-induced cGMP levels were affected by PDE2, whereas the response to nitric oxide donor sodium nitroprusside was slightly but significantly reduced. Interestingly, despite persistently depressed cAMP levels, both cGMP-elevating stimuli were able to completely prevent the PDE2-induced MyoCF phenotype, arguing for a double-tracked mechanism. In conclusion, PDE2 accelerates CF to MyoCF conversion, which leads to greater stiffness in ECTs. Atrial natriuretic peptide- and sodium nitroprusside-mediated cGMP synthesis completely reverses PDE2-induced fibroblast conversion. Thus PDE2 may augment cardiac remodeling, but this effect can also be overcome by enhanced cGMP. The redundant role of cAMP and cGMP as antifibrotic meditators may be viewed as a protective mechanism in heart failure.
Collapse
Affiliation(s)
- C Vettel
- Institute of Pharmacology, University Medical Center Göttingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Biermann D, Bernhardt A, Neef S, Broichhausen I, Jacubeit J, Didié M, Zimmermann WH, Sachweh J, Reichenspurner H, El-Armouche A, Ehmke H, Schwoerer A. Enhanced Ca2+ influx through cardiac L-type Ca2+ channels maintains the systolic Ca2+ transient in early cardiac atrophy induced by mechanical unloading. Thorac Cardiovasc Surg 2014. [DOI: 10.1055/s-0034-1367395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Schwoerer AP, Neef S, Broichhausen I, Jacubeit J, Tiburcy M, Wagner M, Biermann D, Didié M, Vettel C, Maier LS, Zimmermann WH, Carrier L, Eschenhagen T, Volk T, El-Armouche A, Ehmke H. Enhanced Ca²+ influx through cardiac L-type Ca²+ channels maintains the systolic Ca²+ transient in early cardiac atrophy induced by mechanical unloading. Pflugers Arch 2013; 465:1763-73. [PMID: 23842739 PMCID: PMC3898408 DOI: 10.1007/s00424-013-1316-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 06/13/2013] [Accepted: 06/18/2013] [Indexed: 11/04/2022]
Abstract
Cardiac atrophy as a consequence of mechanical unloading develops following exposure to microgravity or prolonged bed rest. It also plays a central role in the reverse remodelling induced by left ventricular unloading in patients with heart failure. Surprisingly, the intracellular Ca2+ transients which are pivotal to electromechanical coupling and to cardiac plasticity were repeatedly found to remain unaffected in early cardiac atrophy. To elucidate the mechanisms underlying the preservation of the Ca2+ transients, we investigated Ca2+ cycling in cardiomyocytes from mechanically unloaded (heterotopic abdominal heart transplantation) and control (orthotopic) hearts in syngeneic Lewis rats. Following 2 weeks of unloading, sarcoplasmic reticulum (SR) Ca2+ content was reduced by ~55 %. Atrophic cardiac myocytes also showed a much lower frequency of spontaneous diastolic Ca2+ sparks and a diminished systolic Ca2+ release, even though the expression of ryanodine receptors was increased by ~30 %. In contrast, current clamp recordings revealed prolonged action potentials in endocardial as well as epicardial myocytes which were associated with a two to fourfold higher sarcolemmal Ca2+ influx under action potential clamp. In addition, Cav1.2 subunits which form the pore of L-type Ca2+ channels (LTCC) were upregulated in atrophic myocardium. These data suggest that in early cardiac atrophy induced by mechanical unloading, an augmented sarcolemmal Ca2+ influx through LTCC fully compensates for a reduced systolic SR Ca2+ release to preserve the Ca2+ transient. This interplay involves an electrophysiological remodelling as well as changes in the expression of cardiac ion channels.
Collapse
Affiliation(s)
- A. P. Schwoerer
- Department of Cellular and Integrative Physiology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
| | - S. Neef
- Department of Cardiology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
| | - I. Broichhausen
- Department of Cellular and Integrative Physiology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
| | - J. Jacubeit
- Department of Cellular and Integrative Physiology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
| | - M. Tiburcy
- Institute of Pharmacology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - M. Wagner
- Institute of Cellular and Molecular Physiology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - D. Biermann
- Department of Cardiovascular Surgery, Center for Cardiology and Cardiovascular Surgery, University Heart Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
| | - M. Didié
- Department of Cardiology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- Institute of Pharmacology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - C. Vettel
- Institute of Pharmacology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - L. S. Maier
- Department of Cardiology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - W. H. Zimmermann
- Institute of Pharmacology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - L. Carrier
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
- Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
- Inserm, U974; CNRS, UMR7215; UPMC UM76, Institut de Myologie, Paris, 75013 France
| | - T. Eschenhagen
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
- Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
| | - T. Volk
- Institute of Cellular and Molecular Physiology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - A. El-Armouche
- Institute of Pharmacology, Heart Research Center, Georg-August-University Goettingen, Goettingen, Germany
- DZHK (German Centre for Cardiovascular Research)—Goettingen, Goettingen, Germany
| | - H. Ehmke
- Department of Cellular and Integrative Physiology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany
- DZHK (German Centre for Cardiovascular Research)—Hamburg/Kiel/Luebeck, Hamburg, Germany
| |
Collapse
|
21
|
Biermann D, Didié M, Wittköpper K, Christalla P, Reichenspurner H, El-Armouche A, Zimmermann WH. Volume- loading in experimental heterotopic heart transplantation. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0032-1332496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Schwoerer AP, Neuber C, Bernhardt AM, Schmechel A, Mearini G, Boknik P, Kirchhefer U, Schmitz W, Ehmke H, Eschenhagen T, Reichenspurner H, El-Armouche A. Mechanical unloading of the rat heart involves marked changes in the protein kinase-phosphatase balance. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0032-1332493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
23
|
Dewenter M, Vettel C, El-Armouche A. [Losmapimod: a novel drug against cardiovascular diseases?]. Dtsch Med Wochenschr 2012; 138:39-42. [PMID: 23250695 DOI: 10.1055/s-0032-1327368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. Preclinical data from in vitro and in vivo studies suggest a protective role of pharmacological p38 inhibition with regard to the development of cardiovascular diseases. This article evaluates the therapeutic potential of this new pharmacological approach and discusses the current clinical data on Losmapimod.
Collapse
Affiliation(s)
- M Dewenter
- Abteilung Pharmakologie, Universitätsmedizin Göttingen, Göttingen
| | | | | |
Collapse
|
24
|
Abstract
Smoking is one of the major avoidable risks for mortality and morbidity. Thus developing new strategies for smoking cessation is a crucial medical challenge. Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist developed especially for smoking cessation. Several trials proved the efficacy of varenicline and its superiority to other medications for smoking cessation (bupropion and nicotine replacement therapy). Varenicline was associated with severe cardiovascular and neuro-psychiatric side effects. This article discusses the current research data on efficacy and safety of varenicline therapy for smoking cessation.
Collapse
Affiliation(s)
- P Christalla
- Abteilung Pharmakologie, Universitätsmedizin Göttingen
| | | | | |
Collapse
|
25
|
Wittköpper K, Emons J, El-Armouche A. Febuxostat. Dtsch Med Wochenschr 2011; 136:1270-4. [DOI: 10.1055/s-0031-1272573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Schmechel A, Grimm M, El-Armouche A, Hoppner G, Schwoerer AP, Ehmke H, Eschenhagen T. Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc Res 2009; 82:100-6. [DOI: 10.1093/cvr/cvp005] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
|
27
|
Wittköpper K, El-Armouche A, Eschenhagen T. Olanzapin. Dtsch Med Wochenschr 2008; 133:1958-62. [DOI: 10.1055/s-0028-1085603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
28
|
Grote-Wessels S, Baba HA, Boknik P, El-Armouche A, Fabritz L, Gillmann HJ, Kucerova D, Matus M, Muller FU, Neumann J, Schmitz M, Stumpel F, Theilmeier G, Wohlschlaeger J, Schmitz W, Kirchhefer U. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 2008; 79:464-71. [DOI: 10.1093/cvr/cvn113] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
29
|
Wittköpper K, Unsöld B, Eschenhagen T, El-Armouche A. Inducible and cardiac specific inhibitor-1 overexpression enhances contractile performance in the murine heart. J Mol Cell Cardiol 2008. [DOI: 10.1016/j.yjmcc.2008.02.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
El-Armouche A, Eschenhagen T. Dopamin: geringer Stellenwert in der Notfallmedizin? Dtsch Med Wochenschr 2007; 132:2654. [DOI: 10.1055/s-2007-993116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
El-Armouche A, Rau T, Eschenhagen T. Herzklappenfehler durch Parkinsonmedikamente? Dtsch Med Wochenschr 2007. [DOI: 10.1055/s-2007-979412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Affiliation(s)
- A El-Armouche
- Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | | | | |
Collapse
|
33
|
Wiechert S, El-Armouche A, Rau T, Zimmermann WH, Eschenhagen T. 24-h Langendorff-perfused neonatal rat heart used to study the impact of adenoviral gene transfer. Am J Physiol Heart Circ Physiol 2003; 285:H907-14. [PMID: 12663262 DOI: 10.1152/ajpheart.00856.2002] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The human genome project has increased the demand for simple experimental systems that allow the impact of gene manipulations to be studied under controlled ex vivo conditions. We hypothesized that, in contrast to adult hearts, neonatal hearts allow long-term perfusion and efficient gene transfer ex vivo. A Langendorff perfusion system was modified to allow perfusion for >24 h with particular emphasis on uncompromised contractile activity, sterility, online measurement of force of contraction, inotropic response to beta-adrenergic stimulation, and efficient gene transfer. The hearts were perfused with serum-free medium (DMEM + medium 199, 4 + 1) supplemented with hydrocortisone, triiodothyronine, ascorbic acid, insulin, pyruvate, l-carnitine, creatine, taurine, l-glutamine, mannitol, and antibiotics recirculating (500 ml/2 hearts) at 1 ml/min. Hearts from 2 day-old rats beat constantly at 135-155 beats/min and developed active force of 1-2 mN. During 24 h of perfusion, twitch tension increased to approximately 165% of initial values (P < 0.05), whereas the inotropic response to isoprenaline remained constant. A decrease in total protein content of 10% and histological examination indicated moderate edema, but actin and calsequestrin concentration remained unchanged and perfusion pressure remained constant at 7-11 mmHg. Perfusion with a LacZ-encoding adenovirus at 3 x 108 active virus particles yielded homogeneous transfection of approximately 80% throughout the heart and did not affect heart rate, force of contraction, or response to isoprenaline compared with uninfected controls (n = 7 each). Taken together, the 24-h Langendorff-perfused neonatal rat heart is a relatively simple, inexpensive, and robust new heart model that appears feasible as a test bed for functional genomics.
Collapse
Affiliation(s)
- S Wiechert
- Institute of Experimental and Clinical Pharmacology, University Erlangen-Nürnberg, 91054 Erlangen, Germany
| | | | | | | | | |
Collapse
|